Erratum

Klaus-Peter Seidler · Swantje Grützmacher · Alexandra Epner · Karin Schreiber-Willnow 1 Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Deutschland 2 Klinik für Psychogene Störungen, Psychosomatische Medizin und Psychotherapie, DRK Kliniken Berlin Wiegmann Klinik, Berlin, Deutschland 3 Klinik für Psychosomatische Medizin und Psychotherapie, Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Deutschland 4 Köln, Deutschland

[1]  P. Vermersch,et al.  Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice , 2016, European Neurology.

[2]  A. Thompson,et al.  Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper , 2016, Multiple sclerosis.

[3]  D. Centonze,et al.  Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  M. Trojano,et al.  Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study , 2015, European Neurology.

[5]  C. Oreja-Guevara,et al.  Observational Safety Study of THC:CBD Oromucosal Spray (Sativex) in Multiple Sclerosis Patients with Spasticity , 2015 .

[6]  C. Vila,et al.  Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. , 2014, Journal of comparative effectiveness research.

[7]  U. Zettl,et al.  Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity , 2014, European Neurology.

[8]  C. Wolfson,et al.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review , 2013, BMC Neurology.

[9]  C. Oreja-Guevara,et al.  Spasticity in multiple sclerosis: results of a patient survey , 2013, The International journal of neuroscience.

[10]  P. Vermersch,et al.  [Epidemiology and clinical assessment of spasticity in multiple sclerosis]. , 2012, Revue neurologique.

[11]  C. Pozzilli,et al.  A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis , 2011, European journal of neurology.

[12]  C. Collin,et al.  A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis , 2010, Neurological research.

[13]  G. Bavikatte,et al.  Approach to spasticity in general practice. , 2009 .

[14]  J. Farrar,et al.  Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. , 2008, Clinical therapeutics.

[15]  C. Collin,et al.  Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis , 2007, European journal of neurology.

[16]  L. Vécsei,et al.  The epidemiology of multiple sclerosis in Europe , 2006, European journal of neurology.

[17]  W. Jost,et al.  Botulinum toxin in patients with multiple sclerosis , 2006, Journal of Neurology.

[18]  C. Young,et al.  Anti-spasticity agents for multiple sclerosis. , 2001, The Cochrane database of systematic reviews.